1. Ai J, Tang Q, Wu Y, Xu Y, Feng T, Zhou R, Chen Y, Gao X, Zhu Q, Yue X, Pan Q, Xu S, Li J, Huang M, Daugherty-Holtrop J, He Y, Xu HE, Fan J, Ding J, Geng M. The Role of Polymeric Immunoglobulin Receptor in Inflammation-induced Tumor Metastasis of Human Hepatocellular Carcinoma. J Natl Cancer Inst. 2011;103 (22):1696-712. 2. Liu H#, Ai J#, Shen A, Chen Y, Wang X, Peng X, Chen H, Shen Y, Huang M, Ding J, Geng M. c-Myc alteration determines the therapeutic response to FGFR inhibitors. Clin Cancer Res. 2016 Jul 11. 3. Yan W, Wang X, Dai Y, Zhao B, Yang X, Fan J, Gao Y, Meng F, Wang Y, Luo C, Ai J*, Geng M*, Duan W*. Discovery of 3-(5'-Substituted)-benzimidazole-5- (1-(3,5-dichloropyridin-4-yl)ethoxy)-1H-indazoles as Potent Fibroblast Growth Factor Receptor Inhibitors: Design, Synthesis and Biological Evaluation. J Med Chem. 2016; 59(14):6690-708. 4. Wang Y, Zhan Z, Jiang X, Peng X, Shen Y, Chen F, Ji Y, Liu W, Shi Y, Duan W, Ding J, Ai J*, Geng M*. Simm530, a novel and highly selective c-Met inhibitor, blocks c-Met-stimulated signaling and neoplastic activities. Oncotarget. 2016;7 (25):38091-104. 5. Song Z, Yang Y, Liu Z, Peng X, Guo J, Yang X, Wu K, Ai J*, Ding J, Geng M*, Zhang A*. Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild and Mutant ALK Kinases. J Med Chem. 2015; 58(1):197-211. 6. Wang L#, Ai J#, Shen Y, Zhang H, Peng X, Huang M, Zhang A, Ding J, Geng M. SOMCL-863, a novel, selective and orally bioavailable small-molecule c-Met inhibitor, exhibits antitumor activity both in vitro and in vivo. Cancer Lett. 2014; 351(1):143-50. |